Atriva Therapeutics GmbH

Industry / private company


Location: Tübingen, Germany (DE) DE

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses (2022) Schreiber A, Viemann D, Schoening J, Schloer S, Zambrano AM, Brunotte L, Faist A, et al. Journal article